Hatanaka T, Kakizaki S, Hiraoka A, Tada T, et al. Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models. J Gastroenterol Hepatol 2025 Jan 6. doi: 10.1111/jgh.16871.
PMID: 39762722